Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
作者信息
Abdulrab Saleem, Al-Maweri Sadeq, Halboub Esam
机构信息
Madinat Khalifa Health Center, Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health and Population, Sana'a, Yemen.
Department of Oral Medicine and Diagnostic Science, Al Farabi Colleges, Riyadh, Saudi Arabia.
出版信息
Med Hypotheses. 2020 Oct;143:109897. doi: 10.1016/j.mehy.2020.109897. Epub 2020 May 30.
Abstract
摘要
相似文献
1
Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.熊去氧胆酸作为一种缓解和/或预防新冠病毒相关细胞因子风暴的候选治疗药物。
Med Hypotheses. 2020 Oct;143:109897. doi: 10.1016/j.mehy.2020.109897. Epub 2020 May 30.
2
On the Alert for Cytokine Storm: Immunopathology in COVID-19.警惕细胞因子风暴：COVID-19 的免疫病理学。
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063. doi: 10.1002/art.41285. Epub 2020 May 10.
3
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.直面争议：白细胞介素-6 与 COVID-19 细胞因子风暴综合征。
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.
4
COVID-19: Some clinical questions after the first 4 months.新冠病毒病（COVID-19）：最初4个月后的一些临床问题
Eur J Clin Invest. 2020 Jul;50(7):e13326. doi: 10.1111/eci.13326. Epub 2020 Jul 5.
5
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.巴瑞替尼，一种具有潜在作用的药物，可以阻止 SARS-COV-2 进入靶细胞，并控制由 COVID-19 引起的细胞因子风暴。
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
6
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.新型冠状病毒肺炎相关细胞因子风暴综合征的改善：与嵌合抗原受体T细胞细胞因子释放综合征的相似之处
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
7
Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.抗炎治疗可能会改善新冠肺炎的临床症状。
Ann Rheum Dis. 2020 Sep;79(9):1253-1254. doi: 10.1136/annrheumdis-2020-217562. Epub 2020 Apr 28.
8
Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.重症新型冠状病毒肺炎、内稳态与有效糖皮质激素治疗的“意外”效果
Clin Immunol. 2020 Oct;219:108550. doi: 10.1016/j.clim.2020.108550. Epub 2020 Jul 31.
9
Surviving the storm: Dealing with COVID-19.挺过风暴：应对新冠疫情
Cell Immunol. 2020 Aug;354:104153. doi: 10.1016/j.cellimm.2020.104153. Epub 2020 Jun 13.
10
Dapsone and doxycycline could be potential treatment modalities for COVID-19.氨苯砜和强力霉素可能是治疗新冠肺炎的潜在方法。
Med Hypotheses. 2020 Jul;140:109768. doi: 10.1016/j.mehy.2020.109768. Epub 2020 Apr 22.
引用本文的文献
1
Fetal programming by the parental microbiome of offspring behavior, and DNA methylation and gene expression within the hippocampus.亲代微生物群对后代行为以及海马体内DNA甲基化和基因表达的胎儿编程。
bioRxiv. 2024 Oct 22:2024.04.12.589237. doi: 10.1101/2024.04.12.589237.
2
Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections.胆汁酸与肠道微生物群的相互作用：感染的调节机制与治疗潜力
Pathogens. 2024 Aug 20;13(8):702. doi: 10.3390/pathogens13080702.
3
Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea.熊去氧胆酸的使用与慢性肝病患者 COVID-19 感染的相关性：韩国一项全国范围内的病例对照研究。
Virol J. 2024 Aug 27;21(1):202. doi: 10.1186/s12985-024-02464-1.
4
Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study.熊去氧胆酸与 COVID-19 感染患者临床结局的相关性：基于人群的队列研究。
JMIR Public Health Surveill. 2024 Oct 7;10:e59274. doi: 10.2196/59274.
5
The Value of Ursodeoxycholic Acid and Mesenchymal Stem Cells in the Treatment of Severe COVID-19.熊去氧胆酸和间充质干细胞在治疗重症新型冠状病毒肺炎中的价值
Microorganisms. 2024 Jun 22;12(7):1269. doi: 10.3390/microorganisms12071269.
6
Bile acids and coronavirus disease 2019.胆汁酸与2019冠状病毒病
Acta Pharm Sin B. 2024 May;14(5):1939-1950. doi: 10.1016/j.apsb.2024.02.011. Epub 2024 Feb 13.
7
Oligosaccharides as Potential Regulators of Gut Microbiota and Intestinal Health in Post-COVID-19 Management.寡糖作为新冠后管理中肠道微生物群和肠道健康的潜在调节剂
Pharmaceuticals (Basel). 2023 Jun 9;16(6):860. doi: 10.3390/ph16060860.
8
The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment.肠道微生物群与 COVID-19 进展的关系：对免疫发病机制和治疗的新认识。
Front Immunol. 2023 May 2;14:1180336. doi: 10.3389/fimmu.2023.1180336. eCollection 2023.
9
Development of HPLC-CAD method for simultaneous quantification of nine related substances in ursodeoxycholic acid and identification of two unknown impurities by HPLC-Q-TOF-MS.建立高效液相色谱-串联四级杆飞行时间质谱法同时测定熊去氧胆酸中 9 种有关物质的含量，并通过高效液相色谱-四级杆飞行时间质谱法对其中 2 种未知杂质进行鉴定。
J Pharm Biomed Anal. 2023 May 30;229:115357. doi: 10.1016/j.jpba.2023.115357. Epub 2023 Mar 23.
10
Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity.肠道微生物群与新型冠状病毒感染及疫苗免疫原性之间的关联。
Microorganisms. 2023 Feb 10;11(2):452. doi: 10.3390/microorganisms11020452.
Zotero 插件